FAIR ACT
See how your representatives voted on this bill.
DeepSyte matches this bill to the issues you care about and shows whether your reps' votes line up — not party, not press releases. Take the 2-minute values quiz to see your alignment.
Alignment with your views
Sign in and take the values quiz to see how this bill lines up with what you've said.
Summary
The FAIR Act establishes a reciprocal approval mechanism allowing the FDA to grant marketing approval for drugs and biologics already approved by trusted international regulatory authorities (European Medicines Agency, UK MHRA, Health Canada, and others designated by HHS) for immediately life-threatening diseases. The bill also permits clinical trials in the U.S. to proceed if authorized by these same trusted authorities, with FDA decisions required within 30 days. The FDA retains authority to withdraw approval if new evidence demonstrates unreasonable safety risks or if the foreign regulator rescinds approval, and must report to Congress within 5 years on the program's effectiveness and impact on patient safety.
Values analysis
Sign in and take the values quiz to get a personalized read on how this bill lines up with your positions.
How your representatives voted
Sign in to see how your representatives voted on this bill.